document incorporate reference incorporate scheringplough corporation part annual report shareholder scheringplough corporation proxy iii statement annual meeting shareholder april item business term scheringplough company refer scheringplough corporation subsidiary indicate context scheringplough corporation hold company incorporate trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company subsidiary scheringplough corporation engage discovery development manufacturing marketing pharmaceutical product worldwide discovery development effort target field human health application field animal health result effort company view animal health application mean maximize return investment discovery development company operate primarily prescription pharmaceutical marketplace appropriate company seek regulatory approval switch prescription product thecount otc status mean extend product life cycle way otc marketplace mean maximize return investment discovery development prescription product include claritin claritind nasonex proventil vancenase vanceril allergyrespiratory eulexin intron pegintron rebetron combination therapy contain rebetol ribavirin capsule intron injection remicade temodar antiinfective anticancer diprolene diprosone elocon lotrisone dermatological imdur integrilin kdur nitrodur cardiovascular andcelestone subutex pharmaceuticals animal health product include cepravin nuflor antimicrobials banamine nonsteroidal antiinflammatory ralgro growth promotant implant otomax otic product broad range vaccine specie parasiticide suture bandage nutritional product foot care otc sun care product include clear away wart remover scholl foot care product lotrimin tinactin antifungal ointment afrin nasal decongestant chlortrimeton antihistamine coricidin drixoral cold decongestant product correctol laxative bain soleil coppertone solarcaine sun care product net sale major product therapeutic category dollar million year end december percent change allergy respiratory claritin nasonex proventil vancenase vanceril allergy respiratory antiinfective anticancer intron arebetron eulexin temodar remicade antiinfective anticancer cardiovascular kdur integrilin nitrodur imdur cardiovascular dermatological lotrisone elocon dermatological pharmaceutical worldwide pharmaceutical animal health foot care otc sun care consolidate net sale meaningful certain amount reclassify sell general administrative expense net sale comply eitf issue account certain sale incentive segment information set forth note consolidated financial statement company annual report shareholder incorporate reference prescription drug introduce known physician pharmacist hospitals manage care organization buy group train professional sale representative sell hospital manage care organization wholesale distributor retail pharmacist prescription product introduce known journal advertise direct mail advertising distribute sample physicians television radio internet print advertising medium animal health product promote veterinarian distributor animal producer foot care otc sun care product sell wholesale retail drug food chain mass merchandiser outletsand promote directly consumer television radio internet print advertising medium company subsidiary license right number patent patent application united states abroad patent patent application relate company significant product include limitation claritin family product intron rebetron combination therapy contain rebetol capsule intron injection pegintron material importance company certain claritin loratadine relate patent expire year specifically loratadine compound patent claritin united states expire compound patent desloratadine active metabolite loratadine expire patent subject litigation describe item legal proceeding worldwide company product sell trademark trademark consider aggregate material importance business protect registration common law united states market product sell raw material essential company available adequate quantity number potential supplier energy expect available company sufficient quantity meet operating requirement seasonal pattern pronounce effect consolidated operation company pharmaceutical industry highly competitive include large company substantial resource research product development advertising promotion field sell support numerous domestic international competitor industry principal competitive technique company product include research development new improved product high product quality varied dosage form strength switch prescription product nonprescription status united states company product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental pressure dispense generic product significantly reduce sale certain product long protect patent datum exclusivity arrangement fda percent percent percent respectively consolidated net sale mckesson hboc inc major pharmaceutical health care product distributor substantially sale united states foreign operation foreign activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition company represent market licensee distribution arrangement approximately employee outside united states foreign operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation restrictive governmental action fluctuation foreign currency exchange rate impact company consolidated financial result additional information foreign operation management discussion analysis operation financial condition segment information company annual report shareholder incorporate reference research development company research activity primarily aim discover develop new enhance prescription product medical commercial significance company sponsor research development expenditure million million million respectively research expenditure represent approximately percent consolidated net sale approximately percent consolidated net sale company research activity concentrate therapeutic area allergic inflammatory disorder infectious disease oncology cardiovascular disease central nervous system disorder company substantial effort direct biotechnology gene therapy immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale product await fda approval march day prior printing report clarinex tablet desloratadine asmanex mometasone furoate allergyrespiratory rebetol capsule pegintron rebetol combination therapy antiinfective government regulation pharmaceutical company subject extensive regulation number national state local agency particular importance united states food drug administration fda jurisdiction company business administer requirement cover testing approval safety effectiveness manufacturing labeling marketing company product extent fda requirement andor review affect resource necessary develop new product bring market united states fda regulate prescription drug switch prescription overthecounter otc status thatregard company recently inform date fda hold joint advisory committee meeting fda pulmonary allergy drug product division otc division consider citizen petition file fda request otc switch loratadine antihistamine market company ongoing basis fda regulate facility procedure manufacture pharmaceutical product united states sale united states product facility manufacture accordance good manufacturing practice gmp establish fda fda periodically inspect company facility procedure assure compliance fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current gmp primarily relate production process control procedure continue evaluate issue raise information provide company connection fda inspection company take extensive measure intend enhance manufacturing process control company note fda inspection report internal review indicate improvement require fda advise company gmp deficiency cite facility inspection report resolve prior grant approval company pende new drug application nda clarinex desloratadine tablet failure comply government regulation result delay release product delay approval new product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction company activity outside united states subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country fda approval approval european medicine evaluation agency obtain product approval product comparable regulatory authority country outside united states european union case obtain prior marketing product country approval process rigorous country country time require approval long shorter require united states approval country assure product approve country international market company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method cost control recent year legislative proposal offer congress state legislature effect major change affect health care system change material company possible addition outpatient prescription drug benefit medicare states pass legislation federal state legislative administrative proposal possible include price patient reimbursement constraint medicine mandate discount expansion exist governmental program new patient population restriction access certain product similar issue arise country outside united states possible predict outcome initiative effect operation cash flow reasonably estimate company subject jurisdiction regulatory enforcement department agency federal trade commission ftc department justice department health human services united states company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy environment date compliance federal state local environmental protection law materially adverse effect company company continue necessary expenditure environmental protection worldwide capital expenditure include approximately million environmental control purpose anticipate continued compliance environmental regulation significantly affect company financial statement competitive position additional information environmental matter legal environmental matter note consolidated financial statement company annual report shareholder incorporate reference employee approximately people employ company december cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement timetotime company contain socalled forwardlooke statement subject risk uncertaintie identify forwardlooke statement use word expect plan estimate forecast project believe anticipate word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result regulatory issue status product approval development program litigation investigation relate expect impact thecompany firstquarter fullyear sale earning manufacturing process control issue describe company effort go forward resolve gmp issue identify fda company internal review certain company manufacture facility remedy fda seek respect issue expect need cost additional remedial action company pendency company nda clarinex remain subject fda approval carefully consider statement understand factor cause actual result differ company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement possible predict identify factor include follow significant portion net sale major pharmaceutical health care product distributor major retail chain united states consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor competitive factor include technological advance attain competitor patent grant competitor new product competitor come market new indication competitive product generic competition company product mature patent expire product increase pricing pressure united states abroad manage care buyer institution government agency unite states development consolidation customer increase pricing pressure result customer great influence prescription decision formulary decision policy government law regulation change law regulation affect domestic international operation enforcement thereof include law regulation result healthcare reform initiative united states state federal level country law regulation relate trade antitrust monetary fiscal policy taxis price control possible nationalization patent position highly uncertain patent dispute unusual adverse result patent dispute preclude commercialization product negatively impact sale exist product result injunctive relief payment financial remedy uncertaintie fda approval process regulatory approval process nonus country include limitation delay approval new product failure meet gmp establish fda governmental authority result delay release product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction resolution manufacturing issue fda discuss report potential impact issue company firstquarter fullyear sale earning subject substantial risk uncertaintie risk uncertainty include time scope duration resolution manufacturing issue depend ability company assure fda quality reliability manufacturing system control extent remedial prospective obligation undertake company difficulty product development pharmaceutical product development highly uncertain product appear promise development fail reach market numerous reason found ineffective harmful effect clinical preclinical testing fail receive necessary regulatory approval turn economically feasible manufacturing cost factor precluded commercialization proprietary right efficacy safety concern respect market product scientifically justified leading recall withdrawal decline sale major product claritin intron arebetron combination therapy rebetol capsule account material portion company revenue major product claritin intron arebetron combination therapy rebetol subject problem loss patent protection previously unknown effect new effective treatment introduce impact revenue significant failure company foresee correct system commercial arrangement address new european currency euro legal factor include product liability claim litigation government investigation patent dispute competitor environmental concern preclude commercialization product negatively affect profitability exist product economic factor company control include change inflation interest rate foreign currency exchange rateschange tax law include change relate taxation foreign earning change accounting standard promulgate american institute certify public accountant financial accounting standard board securities exchange commission adverse company item property company corporate headquarters locate kenilworth new jersey principal manufacturing facility locate kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina australia belgium canada colombia france germany ireland italy japan mexico singapore spain company principal research facility locate kenilworth union new jersey palo alto san diego california elkhorn nebraska major portion property own company property maintain adequately insure good operating condition company manufacture facility capacity consider appropriate meet company need item legal proceeding subsidiarie company defendant lawsuit involve approximately plaintiff arise use synthetic estrogen mother plaintiff virtually lawsuit pharmaceutical company name defendant female plaintiff claim injury include cancerous precancerous lesion vagina cervix multiplicity pregnancy problem number suit involve infant birth defect bear daughter mother take drug total claim defendant suit amount billion possible precisely predict outcome proceeding management opinion remote material liability excess accrue incur company party involve environmental cleanup action proceeding comprehensive environmental response compensation liability act commonly know superfund equivalent state law action proceeding seek require owner operator facility treat store disposed hazardous substance transporter generator substance remediate contaminate facility andor reimburse government private party cleanup cost company owner operator transporter generator allege potentially responsible party prp allege generator hazardous substance find certain facility proceed government private litigant allege prp include company jointly severally liable cleanup requirement cost joint liability allege prp share cleanup cost frequently determine basis factor include type quantity hazardous substance allocation process vary greatly facility facility year complete company potential share cleanup cost depend prp involve action proceed insurance coverage available indemnity contract contribution right prps possible predict certainty outcome action proceed management opinion remote material liability excess amount accrue incur resident vicinity publicly own wastewater treatment plant barceloneta puerto rico file lawsuit plant operator numerous company discharge plant include subsidiary company damage injunctive relief relate odor come plant connect sewer lawsuit class action claim damage million lawsuit early stage discovery possible predict outcome company defendant approximately antitrust action commence start state federal court independent retail pharmacy chain retail pharmacy consumer plaintiff allege price discrimination andor conspiracy company defendant restrain trade jointly refuse sell prescription drug discount price plaintiff federal case class action behalf approximately twothirds retail pharmacy united states allege pricefixe conspiracy company february agree settle federal class action total million pay united states district court illinois approve settlement federal class action june june seventh circuit court appeal dismiss appeal settlement subject review defendant settle class action proceed trial september trial end november direct verdict defendant favor april certain plaintiff federal class action commence purport class action united states district court illinois company defendant settle previous federal class action complaint allege defendant conspire implement settlement commitment follow settlement discuss district court deny plaintiff motion preliminary injunction hear company settle state retailer action california alabama settlement amount material company june alabama supreme court reverse denial motion judgment thepleading alabama retailer case court hold alabama antitrust law apply conspiracy allege interstate commerce base rule alabama retailer case dismiss subsequently district attorney judicial circuit file complaint behalf alabama consumer state deceptive trade practice act company settle dispose state consumer case settlement amount material company company settle group similar federal antitrust case bring food drug chain retailer independent retailer store comprise prescription drug retail market settlement amount material company plaintiff antitrust action generally seek treble damage unspecified injunction allegedly unlawful conduct company believe antitrust action merit defend vigorously march company notify united states federal trade commission ftc investigate company pharmaceutical company conspire fix prescription drug price company believe action lawful proper cooperating investigation possible predict outcome investigation result imposition fine penalty injunctive administrative remedy october company receive subpoena attorney office eastern district pennsylvania pursuant health insurance portability accountability act concern company contract pharmacy benefit manager pbms manage care organization provide disease management service connection marketing pharmaceutical product appear subpoena number address industry participant inquiry thing pharmaceutical marketing practice government inquiry appear focus company disease management marketing program arrangement comply federal health care law value disease management program marketing program arrangement include calculation rebate government company cooperate investigation possible predict outcome investigation include imposition fine penalty injunctive administrative remedy company predict investigation affect marketing practice sale february geneva pharmaceuticals inc geneva submit abbreviate new drug application anda food drug administration fda seek market generic form claritin united states year expiration company patent geneva allege certain company claritin patent invalid unenforceable claritin patent material company business march company file suit federal court seek rule geneva anda submission constitute willful infringement company patent challenge company patent merit company believe prevail suit litigation assurance company prevail copley pharmaceutical inc teva pharmaceuticals inc novex pharma zenith goldline pharmaceutical individually notify company submit anda fda seek market certain generic form claritin united states expiration certain company patent andrx pharmaceuticals llc mylan pharmaceuticals inc esi lederle inc lederle impax laboratories inc similar submission february alpharma uspd inc similar submission allege patent invalid unenforceable case company file file suit federal court seek rule applicable anda submission propose marketing generic product constitute willful infringement company patent challenge patent merit company believe prevail suit litigation assurance company prevail january hoffmannla roche inc file action company united states district court new jersey france germany allege company pegintron peginterferon alfab infringe hoffmannla roche inc patent certain pegylate interferon company believe prevail suit litigation assurance company prevail company respond investigation department health human services department justice certain state certain industry company practice average wholesale price awp investigation include department justice review merit federal action file private entity behalf united states united states district court southern district florida investigation united states attorney office district massachusett inter alia awp set pharmaceutical company certain drug improperly exceed average price pay dispenser consequence result unlawful inflation certain government drug reimbursement base awp wholesale acquisition cost united states attorney office district massachusetts investigate company sale product repackage sale manage care organization include company medicaid good price calculation company cooperate investigation possible predict outcome investigation include imposition fine penalty injunctive administrative remedy quarter company generic subsidiary warrick pharmaceuticals sue state texas lawsuit allege warrick supply state false report wholesale price cause state pay medicaid claim prescription warrick albuterol sulfate solution higher justify level state seek damagesof million warrick include treble damage penalty possible predict outcome litigation result imposition fine penalty injunctive administrative remedy ftc investigate possible anticompetitive effect settlement patent lawsuit company lederle company upshersmith inc upshersmith lawsuit settle related generic version kdur company longacte potassium chloride product subject abbreviate new drug application file lederle upshersmith investigation ongoing company believe action lawful proper cooperating investigation possible predict outcome investigation result imposition fine penalty injunctive administrative remedy january jury find company prime pac prrs porcine respiratory reproductive syndrome vaccine infringe patent own boehringer ingelheim vetmedica inc injunction issue august bar sale company vaccine company file posttrial motion currently pende reversal jury verdict new trial company believe prevail posttrial motion appeal litigation assurance company prevail february company state press release fda conducting inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current gmp primarily relate production process control procedure company note press release process control issue lead reduce sale certain product marketplace result quarter year sale earning lower expect day february lawsuit file united states district court district new jersey company certain name officer allege violation section securities exchange act rule promulgate thereunder additional lawsuit tenor follow file plaintiff suit file march day prior printing report purport represent class shareholder purchase share company stock july february date press release litigation early stage company believe substantial defense intend defend suit vigorously item submission matter vote security holder applicable executive officer registrant follow information executive officer include accordance iii item officer elect serve year successor shall duly elect current position business experience age richard jay kogan present position chairman board president chief executive chief executive officer officer president chief operating officer raul cesan present position president chief executive vice president operating officer president scheringplough pharmaceuticals joseph connor present position executive vice president senior vice president general counsel general counsel jack wyszomierski present position executive vice president vice president treasurer chief financial officer geraldine foster present position senior vice president investor relation andcorporate communication daniel nichols present position senior vice president tax john ryan present position senior vice president vice president human resource human resource scheringplough pharmaceuticals douglas gingerella present position vice president corporate staff vice president corporate audits audits thomas kelly present position vice president controller robert lyons present position vice president corporate information service kevin moore present position vice president staff vice president treasurer assistant treasurer john present position vice president president technical operations president schering schering laboratory technical operation joseph larosa present position staff vice president staff vice president commercial law secretary associate senior legal director general counsel legal director item market registrant common equity relate stockholder matter common share dividend share price datum approximate number holder record set forth company annual report shareholder incorporate reference item select financial datum sixyear select financial statistical datum set forth company annual report shareholder incorporate reference item management discussion analysis financial condition result operation management discussion analysis operation financial condition set forth company annual report shareholder incorporate reference item quantitative qualitative disclosure market risk market risk disclosure set forth management discussion analysis operation financial condition company annual report shareholder incorporate referenceitem financial statement supplementary datum consolidate balance sheet december relate statement consolidated income consolidated shareholder equity consolidated cash flow year period end december note consolidated financial statement independent auditor report deloitte touche llp date february quarterly datum set forth company annual report shareholder incorporate reference item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information concern director nominee director set forth company proxy statement annual meeting shareholder april incorporate reference information require executive officer include file caption executive officer registrant item executive compensation executive compensation information set forth company proxy statement annual meeting shareholder april incorporate reference item security ownership certain beneficial owner management information concern security ownership certain beneficial owner management set forth company proxy statement annual meeting shareholder april incorporate reference item certain relationship relate transaction information concern certain relationship relate transaction set forth company proxy statement annual meeting shareholder april incorporate reference item exhibit financial statement schedule report form financial statement follow consolidated financial statement independent auditor report include company annual report shareholder incorporate reference statement consolidated income year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement independent auditor reporta financial statement schedule independent auditor report schedule valuation qualifying account schedule included omit applicable require require information set forth financial statement note thereto column omit schedule file omit information applicable financial statement percent own company account equity method omit consider individually aggregate constitute significant subsidiary exhibit exhibit number description complete copy certificate incorporation amend currently effect incorporate reference exhibit company quarterly report period end june form certificate amendment certificate incorporation incorporate reference exhibit company quarterly report period end june form certificate amendment certificate incorporation incorporate reference exhibit company quarterly report period end march form file complete copy bylaw amend currently effect incorporate reference exhibit company registration statement form file amendment bylaw effective september incorporate reference exhibit company quarterly report period end september form file right agreement company bank new york date june incorporate reference exhibit form file company june file indenture date november company chase manhattan bank trustee incorporate reference exhibit company registration statement form file form participation right agreement company chase manhattan bank national association trustee incorporate reference exhibit company registration statement form amendment file company executive incentive plan amend trust relate thereto plan incorporate reference exhibit company quarterly report period end march form executive incentive plan amend restate october file document file trust agreement incorporate reference exhibit company annual report amendment trust agreement incorporate reference exhibit company quarterly report period end march form amend restate define contribution trust file document file company stock incentive plan amend incorporate reference exhibit company annual report form file company stock incentive plan amend incorporate reference exhibit company annual report form file amendment december incorporate reference exhibit company annual report form file company stock incentive plan incorporate reference exhibit company quarterly report period end september form amendment stock incentive plan incorporate reference exhibit company quarterly report period end march form file employment agreement company richard jay kogan amend incorporate reference exhibit eii company annual report amendment incorporate reference exhibit company quarterly report period end june form second amendment incorporate reference exhibit eii company annual report form amendment incorporate reference exhibit company quarterly report period end september form fourth amendment incorporate reference exhibit company quarterly report period end march form fifth amendment incorporate reference exhibit eii company annual report file form employment agreement company executive officer effective change control incorporate reference exhibit eiv company annual report form amendment incorporate reference exhibit company quarterly report period end september form file iii employment agreement company raul cesan incorporate reference exhibit evi company annual report file employment agreement company robert luciano amend incorporate reference exhibit company annual report amendment incorporate reference exhibit company quarterly report period end june form second amendment incorporate reference company annual report amendment incorporate reference exhibit company quarterly report period end march form file agreement company robert luciano incorporate reference exhibit company quarterly report period end march form file amend restate director defer compensation plan trust relate thereto incorporate reference exhibit company quarterly report period end september form trust agreement incorporate reference exhibit company annual report amendment trust agreement incorporate reference exhibit company quarterly report period end march form amend restate define contribution trust file document exhibit file supplemental executive retirement plan trust relate thereto incorporate reference exhibit company quarterly report period end march form amendment incorporate reference exhibit company quarterly report period end september form second amendment supplemental executive retirement plan effective october file document amend restate trust agreement incorporate reference exhibit company annual report form file amend restate director stock award plan incorporate reference exhibit company quarterly report period end september form file defer compensation plan incorporate reference exhibit company quarterly report period end september form deferred compensation plan amend restate october file document file amend restate director defer stock equivalency program incorporate reference exhibit company quarterly report period end september form file company form split dollar agreement relate collateral assignment company executive officer incorporate reference exhibit company annual report form amendment incorporate reference exhibit company quarterly report period end march formq file company retirement benefit equalization plan second amendment effective october file document incorporate reference exhibit company quarterly report period end march form amendment incorporate reference exhibit company quarterly report period end september form file computation ratio earning fix charge file document financial section company annual report shareholder exception portion say annual report specifically incorporate reference file document report shall deem file subsidiary registrant file document consent expert counsel file document power attorney file document compensatory plan contract arrangement